+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
679 locations
M

Actively Recruiting

Researchers are evaluating the efficacy and safety of Eloralintide LY3841136 for adults with osteoarthritis of the knee who are overweight or obese and experiencing knee pain. This Phase 3, randomized, double-blind, placebo-controlled study aims to assess how well Eloralintide works in reducing body weight and improving knee pain. The trial is sponsored by Eli Lilly and Company and includes two independent studies under a master protocol. Participants will receive once-weekly subcutaneous injections of either Eloralintide or placebo. The study includes parallel treatment arms comparing Eloralintide to placebo in adults with osteoarthritis knee pain and weight concerns. Treatment lasts for approximately 64 weeks, with dosing and assessments occurring regularly. The study also allows for a total participation duration of about 75 weeks, including screening. During the trial, participants will undergo various assessments including measurements of body weight, knee pain using the Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale, physical function, blood pressure, inflammatory markers, and walking distance. Researchers will monitor medication use and collect data on quality of life and biochemical markers. Safety and pharmacokinetics of Eloralintide are also tracked throughout the study.

Age: 18Years +All GendersPhase 3
147 locations